Press Releases and News

Landos Biopharma to Present at BioTech Showcase 2018

December 20 2017

Landos Biopharma to Present at BioTech Showcase 2018

BLACKSBURG, VA, December 19, 2017 – Landos Biopharma, Inc., an emerging biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases, will present at the Biotech Showcase during BioWeek in San Francisco. Along with the 36th J.P. Morgan Annual Healthcare Conference, this event is considered one of the year’s most important investor conferences and attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts.

Founder and Chairman of Landos Biopharma, Dr. Josep Bassaganya-Riera, will present an update on the company and a review of its novel oral therapeutics for autoimmune diseases on Tuesday, January 9 at 2 p.m. PT. The conference will be held at the Hilton San Francisco Union Square in San Francisco, CA. .

Landos’ lead therapeutic asset, BT-11, is expected to enter clinical trials in 2018 and conclude Phase 1 clinical testing by early 2019. BT-11 is a first-in-class, locally-acting oral therapeutic being evaluated for treatment of moderate to severe Crohn’s disease and ulcerative colitis. BT-11 intercepts inflammatory bowel disease (IBD) by decreasing the production of inflammatory mediators and increasing anti-inflammatory molecules within the gastrointestinal tract. BT-11 has shown a benign safety profile in animal models and is currently advancing toward an Investigational New Drug (IND) filing.

Current therapies for autoimmune diseases, a $100 billion market, have limited efficacy and possess significant side effects. Landos’ mission is to accelerate the development of safer, more effective therapeutics for autoimmune diseases including IBD, Crohn’s disease, and ulcerative colitis. Landos BioPharma is poised to offer patients with IBD, which impacts 1.6 million Americans and 5 million people worldwide, a novel approach to treating their painful and debilitating disease.

For more information about Landos Biopharma, visit www.landosbiopharma.com.

For more information about the BioTech Showcase visit https://ebdgroup.knect365.com/biotech-showcase/.

###

About Landos Biopharma, Inc.

Landos Biopharma, Inc. is an emerging biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a novel, locally-acting small molecule targeting inflammatory bowel disease (IBD) that is expected to enter clinical testing for Crohn’s disease in 2018. Landos also has a robust pipeline of compounds for other autoimmune diseases. Landos is headquartered in Blacksburg, VA. For more information, please visit www.landosbiopharma.com or follow us on Twitter @landosbio.

Landos Biopharma Company Contact:

info@landosbiopharma.com